Trial · NCT00795366
Vasopressin Versus Catecholamines for Cerebral Perfusion Pressure Control in Brain Injured Trauma Patients
NCT00795366, Not applicable, Completed, University of Miami; results first posted 2014-12-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Vasopressin Versus Catecholamines for Cerebral Perfusion Pressure Control in Brain Injured Trauma Patients. Trials, record NCT00795366. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00795366
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Vasopressin Versus Catecholamines for Cerebral Perfusion Pressure Control in Brain Injured Trauma Patients
- NCT number
- NCT00795366
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 96 participants, actual
- Lead sponsor
- University of Miami
- Conditions
- Traumatic Brain Injury
- Interventions
- arginine vasopressin, Standard catecholamine
- First posted
- 2008-11-21
- Last updated
- 2014-12-12
- Results first posted
- 2014-12-12
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time ICP >20 | The number of hours during the first 5 days of intracranial pressure monitoring | The number of hours that participants remained with intracranial pressure above 20 mmHg |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Time ICP >20 | The number of hours during the first 5 days of intracranial pressure monitoring | Intent-to-Treat | Hours | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time ICP >20 | AVP, Arginine Vasopressin | 1.7 | Standard Deviation 1.8 | Hours | |
| Time ICP >20 | Standard Catecholamine | .9 | Standard Deviation 2.6 | Hours |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | AVP, Arginine Vasopressin | 42 | |
| Overall Study | STARTED | Standard Catecholamine | 54 | |
| Overall Study | COMPLETED | AVP, Arginine Vasopressin | 42 | |
| Overall Study | COMPLETED | Standard Catecholamine | 54 | |
| Overall Study | NOT COMPLETED | AVP, Arginine Vasopressin | 0 | |
| Overall Study | NOT COMPLETED | Standard Catecholamine | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Death | General disorders | AVP, Arginine Vasopressin | 6 | 42 | 6 |
| serious | Death | General disorders | Standard Catecholamine | 6 | 54 | 6 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | AVP, Arginine Vasopressin | ||
| Total, all-cause mortality | Standard Catecholamine | ||
| Total, other adverse events | AVP, Arginine Vasopressin | 0 | 42 |
| Total, other adverse events | Standard Catecholamine | 0 | 54 |
| Total, serious adverse events | AVP, Arginine Vasopressin | 6 | 42 |
| Total, serious adverse events | Standard Catecholamine | 6 | 54 |
Source ClinicalTrials.gov
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| AVP, Arginine Vasopressin vs Standard Catecholamine: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00795366
GET https://conductscience.org/api/trials/v1/NCT00795366/registered